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Abstract
Background: The search for genetic factors underlying autism spectrum disorders (ASD) has led to the identification
of hundreds of genes containing thousands of variants that differ in mode of inheritance, effect size, frequency, and
function. A major challenge involves assessing the collective evidence in an unbiased, systematic manner for their
functional relevance.
Methods: Here, we describe a scoring algorithm for prioritization of candidate genes based on the cumulative
strength of evidence for each ASD-associated variant cataloged in AutDB (also known as SFARI Gene). We retrieved
data from 889 publications to generate a dataset of 2187 rare and 711 common variants distributed across 461 genes
implicated in ASD. Each individual variant was manually annotated with multiple attributes extracted from the original
report, followed by score assignment using a set of standardized parameters yielding a single score for each gene.
Results: There was a wide variation in scores; SHANK3, CHD8, and ADNP had distinctly higher scores than all other
genes in the dataset. Our gene scores were significantly correlated with other recently published rankings of ASD
genes (RSpearman = 0.40–0.63; p< 0.0001), providing support for our scoring algorithm.
Conclusions: This new resource, which is freely available, for the first time aggregates on one-platform variants
identified from various study types (simplex, multiplex, multigenerational, and consanguineous families), from both
common and rare variants, and also incorporates their putative functional consequences to arrive at a genetically and
biologically driven ranking scheme. This work represents a major step in moving from simply cataloging autism
variants to using data-driven approaches to gain insight into their significance.
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Background
Autism spectrum disorder (ASD) is a clinical diagnosis
defined by neurodevelopmental impairments in two do-
mains: persistent deficits in social reciprocity and com-
munication across multiple contexts, together with
restricted, repetitive patterns of behavior [1]. Individuals
with ASD can display a broad clinical profile with vary-
ing severity in the core symptoms and often accompan-
ied by medical comorbidities. With onset in the first
years of life, ASD entails a life-long condition with di-
verse outcomes in adulthood [2]. The prevalence of ASD
has been estimated as high as 1 in 68 children [3], yet an
understanding of the biological mechanisms underlying
ASD remains unclear, hampering attempts to develop
specific molecular diagnostics or targeted therapeutics.
A multifactorial etiological model for ASD is being in-
creasingly recognized. Several epidemiological studies
have firmly established a genetic component underlying
ASD with heritability estimates ranging from 50–90 %
depending on the study parameters [4–6]. Consequently,
numerous efforts to identify genes associated with ASD
risk have been undertaken in hopes of inferring molecu-
lar pathways or surrogate markers associated with clin-
ical manifestations of ASD. The ability to screen large
cohorts using high-throughput genomic technologies
has led to the discovery of hundreds of candidate genes
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containing thousands of variants, highlighting enormous
genetic heterogeneity in ASD [7–10]. Although the sig-
nificance of the vast majority of identified variants re-
mains unresolved, a subset of genes have been found to
be highly penetrant for ASD based on recurrent findings
of rare, de novo, damaging variants in probands [11].
While initial estimates suggested between 350 and 400
autism susceptibility genes [12], more recent statistical
models predict that well over 1000 genes may eventually
be associated with ASD [13, 14]. Despite the incredible
insight into the molecular genetics of ASD that these
studies have provided, the diversity in study design, the
significant variance in sample sizes and replication co-
horts, and the use of different statistical models have re-
sulted in a large set of candidate genes that are difficult
to compare on a single platform. Moreover, within any
given ASD candidate gene, multiple variants may be
found, each with its own associated risk [15], further
complicating a clear understanding of their relevance
with respect to autism. To address these challenges, da-
tabases of ASD risk genes have been established in at-
tempts to aggregate the ever-increasing number of
candidate genes implicated in this disorder [16, 17].
However, only recently have strides been made towards
developing methodologies for quantitative assessment of
ASD risk genes [13, 18–20]. For example, transmission
and de novo association (TADA) analysis was developed
to identify risk-conferring genes by integrating rare de
novo and inherited genetic variations from high-
throughput, whole exome sequencing (WES) studies of
large ASD cohorts such as the Autism Sequencing Con-
sortium (ASC) and the Simons Simplex Collection (SSC)
[11, 21]. While TADA analysis has proven to be a critical
first step, further assessment strategies are required to
fully integrate the complete spectrum of ASD genetic
variations and consider all potential attributes that are
likely to be encountered in patients evaluated in ASD
clinics.
The Gene Scoring module (https://gene.sfari.org/autdb/
GS_Home.do) of Simons Foundation Autism Research
Initiative (SFARI) was created as a means for evaluation of
candidate genes on a discrete or categorical scale taking
into account the strength of genetic evidence linking a
gene to ASD [22]. A set of scoring criteria was developed
to assess different types of evidence, methodologies, and
variability reported in the genetic studies of ASD [22].
Here, we have extended this initial work to incorporate a
systematic evaluation of diverse types of genetic variants
implicated in ASD. Our approach is based on assessment
of multiple attributes of an ASD variant including mode
of inheritance, effect size, and variant frequency in the
general population. In this study, we report a consolidated
gene score by summing the various evidence scores gener-
ated for each individual variant of an ASD-implicated
gene. Next, we compared the gene scores generated in this
study with the expert-led SFARI Gene Scoring module as
well as the top ranking ASD genes identified in simplex
families [11, 23]. We found strong concordance between
our ASD gene ranking strategy and the other three ap-
proaches [11, 23]. Using our model, we prioritized a larger
set of genes including SHANK3, CHD8, ADNP, MET,
CNTNAP2, and others derived from the most complete
collection of genetic variations associated with ASD ori-
ginating from simplex, multiplex, multigenerational, and
consanguineous families.
Methods
AutDB catalog of genetic variations associated with ASD
The AutDB database (also known as SFARI Gene) was
first released in 2007 as an online portal providing a
comprehensive, up-to-date resource for ASD candidate
genes identified in peer-reviewed scientific publications
[16]. We have since expanded the ASD gene database to
include detailed annotation of both rare and common
genetic variations extracted from original scientific re-
ports. In this study, rare variants are defined as those
with a population frequency <1 %; common variants are
defined as those found in the general population at a fre-
quency of ≥1 %. Annotated variants in AutDB include
single nucleotide variants (SNVs), insertion-deletion var-
iants (indels), single gene copy number variants (CNVs
occurring within a gene), and chromosomal rearrange-
ments disrupting a single gene thereby capturing the
wide range of potentially pathogenic genetic variations
identified in ASD cohorts. AutDB is continuously main-
tained by scheduled quarterly releases in order to pro-
vide the most up-to-date resource for the ASD genetics
community. The data freeze of January 2015 was used
for building the input dataset as described below.
Input dataset
We performed several filtration steps to generate a data-
set of ASD-specific variants to use in the scoring process
(Additional file 1: Figure S1A). Annotated rare variants
were excluded if they were identified in probands lacking
a confirmed diagnosis of ASD (e.g., rare variants in
ASD-associated genes that had been identified in pa-
tients presenting with intellectual disability or epilepsy
but without ASD). Next, we excluded rare ASD-
associated CNVs lacking statistical significance as deter-
mined by either the absence of a reported p value or a p
value greater than 0.05. A total of 2187 rare variants
remained after variant filtration. Annotated common
variants were excluded from variant scoring if they were
identified in cohorts lacking a confirmed diagnosis of
ASD, such as common variants in ASD-associated genes
found associated with other neuropsychiatric disorders
such as schizophrenia and bipolar disorder. This filtration
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process yielded a dataset of 771 common variants associ-
ated with ASD.
Variant scoring
Each individual variant included in the Human Gene Mod-
ule of AutDB was manually annotated with 17 standardized
descriptors providing a level of variant-specific detail unique
to AutDB. These include significance of genetic association,
family structure (simplex, multiplex, multigenerational, or
consanguineous), zygosity (heterozygous, homozygous, or
hemizygous), inheritance pattern (de novo or transmitted),
the type of variant (missense, nonsense, etc.), and the func-
tional effect of the variant (Additional file 2).
The functional effect of each variant represents a scor-
ing criteria shared by both rare and common variants
and is based on the reported results from the publica-
tion’s experimental analysis or in silico prediction. Then
manual curation of these reported results was used to
place the variant into one of four functional effect categor-
ies, with increasing weight given to variants likely to cause
a functional biological effect (Additional file 3: Table S1).
Variant Specificity to ASD, and Variant Inheritance and
Segregation pattern of rare variants (referred to as scoring
terms “R1” and “R2,” respectively) were assigned with
scores reflecting the strength of the association of the vari-
ant to ASD (Additional file 3: Table S2). For instance, the
R1 scoring term provides increasing weight based on the
variant’s association with ASD and its absence in control
populations included in the study or in large data-
bases of human genetic variations such as dbSNP
(http://www.ncbi.nlm.nih.gov/SNP/), the 1000 Genomes
Project (http://www.1000genomes.org), or the NHLBI
Exome Variant Server (http://evs.gs.washington.edu/EVS/).
Similarly, the R2 scoring category gives increasing
weight to variants exhibiting a clear segregation pat-
tern in individuals exhibiting ASD symptoms within a
pedigree. Finally, “RG5” considers the unique statis-
tical improbability of finding multiple de novo loss-
of-function (LOF) variants in a single gene in ASD
cases compared to controls [9]. The “RG6” category is
a similar scoring factor that adds additional weight to
rare bi-allelic LOF variants identified in consanguin-
eous families. Owing to their unique genetic architec-
ture and contributions to ASD as compared to rare
variants [4], common variants were annotated using a
separate set of scoring criteria. These are summarized
by the “CG1” score, which considers the reported
odds ratio and associated p value for a variant, and
the “CG2” score, which provides increasing weight if
the common variant was replicated in a second co-
hort of ASD individuals within the same study and/or
in a new study (Additional file 3: Table S3).
Finally, we developed a comprehensive algorithm that
aggregates the sub-scores from each of the categories for
every variant in a given gene, weights each scoring sub-
category relative to each other based on their import-
ance to ASD linkage (based on published evidence and
expert opinion), and compiles a single summary score
for each rare and common variant described (Additional
file 1: Figure S1B and S1C, respectively). The sum of all
scored rare variants and all scored common variants
were then calculated to generate a total rare variant
score (RVS) and/or total common variant score (CVS)
for any given gene.
Results
ASD risk variant distributions
The global landscape of variants associated with ASD
analyzed in this study is summarized in Fig. 1. Overall,
there were 2187 rare variants and 711 common variants
in our dataset. These data were retrieved from 889 sci-
entific publications of which 584 (65.7 %) reported only
on rare variants, 266 (29.9 %) reported only on common
variants, and only 39 (4.4 %) reported on both rare and
common variants associated with ASD (Fig. 1a). The
variants were distributed in 461 genes of which 261
(56.6 %) included only rare variants, 120 (26.0 %) in-
cluded only common variants, and 80 (17.4 %) genes
Fig. 1 Global overview of the data in this study. a A pie chart showing
the number of publications reporting only common (red), rare (blue),
or both common and rare (green) genetic variants associated with
autism spectrum disorder (ASD) in our database. b A pie chart
showing the number of genes including only common (red), rare
(blue), or both common and rare (green) genetic variants associated
with ASD in our database. c A distribution of the common (red) and
rare (blue) genetic variation in our database within four mutation
categories: nonsynonymous, synonymous, non-coding, and copy
number variations (CNVs)
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included both rare and common variants (Fig. 1b).
Examination of the spectrum of variants in our database
revealed that the majority of rare variants associated
with ASD are nonsynonymous in the coding region
(71.2 %), whereas most common variants are non-coding
(88.9 %) (Fig. 1c).
ASD risk genes scoring
To assess the strength of evidence linking a candidate
gene to ASD, we computed two scores for each gene:
(1) rare variant score (RVS) that is based on the
cumulative evidence of all rare variants within a par-
ticular gene, and (2) common variant score (CVS)
which is based on the cumulative evidence of all
common variants that are associated with a particular
gene (Additional file 4: Table S4). Both RVSs and
CVSs varied remarkably between genes (Fig. 2a, b)
with SHANK3 having the highest RVS (RVS = 346)
and MET having the highest CVS (CVS = 85). Not-
ably, both RVS and CVS were significantly correlated
with the number of annotated variants per gene (r =
0.84 and r = 0.70, respectively; p < 0.0001; Fig. 2c, d),
which were significantly dependent on the number of
publications per gene (r = 0.70 and r = 0.69, respect-
ively; p < 0.0001; Fig. 2e, f ). No correlation was found
between either RVS or CVS and the coding sequence
length of the gene. Next, we computed a total gene
score (TGS) as the sum of RVS +CVS for each gene. The
Fig. 2 Distributions of rare variant scores (RVS) and common variant scores (CVS). The distributions of the natural logarithm of genes’ RVS and
genes’ CVS are depicted as histograms (a, b, respectively), and as a function of variant counts (c, d for rare and common variants, respectively).
Both RVS and CVS are significantly correlated with the number of variants per gene (r = 0.84 and r = 0.70, respectively; p < 0.0001). e, f The
obvious association between the number of variants and the number of publication per gene (r = 0.70 and r = 0.69, respectively; p < 0.0001)
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TGS of all the genes in our database had a log-normal dis-
tribution with a geometric mean of TGS = 9.03 ± 3.06
(Fig. 3a). Notably, three genes (SHANK3, CHD8, and
ADNP) had distinctively higher scores than other genes in
the database.
To examine the effect of variant count on TGS, we
ran a multivariate linear regression analysis using
both rare and common variant counts as possible
predictors. The resulting regression model explained
only 50 % (adjusted R2 = 0.502) of the variation in
TGS with both rare and common variants contribut-
ing significantly to this variation (B = 0.83 and B =
0.48 for rare and common variants; p< 0.0001).
Figure 3b displays the expected ln(TGS) scores of the
genes according to this model compared to their ob-
served ln(TGS). Six genes (RBFOX1, RIMS3, MBD1,
MBD3, FABP5, and FABP7) had ln(TGS) that was sig-
nificantly lower than their expected ln(TGS) accord-
ing to this model (p< 0.01). Only two genes, MET and
MSNP1AS, had ln(TGS) that were significantly higher
than their expected score (p< 0.01).
Comparison to other ASD risk genes datasets
Next, we compared the results of our gene scoring
approach to the results of three other recently
published ASD-related gene sets that used other
prioritization strategies. Figure 4 summarizes the re-
sults of these analyses. Of the 461 genes included in
our study, 38 (8.2 %) were also included in all other
gene sets and 160 (34.7 %) were exclusively repre-
sented in our AutDB (Fig. 4a). Overall, there was a
strong agreement between our gene scoring approach
and the other three approaches. Specifically, TGSs
were significantly correlated with gene categories in
the community-based SFARI gene scoring module
[22] (Fig. 4b; RSpearman = −0.63; p< 0.0001). Interest-
ingly, there were few genes with TGS that deviated
from the distribution of scores in their category. In
addition, there were 169 genes not previously scored
by the expert-led SFARI Gene Scoring initiative that were
included in our analysis (Fig. 4a). These genes had a wide
distribution of TGS covering almost the entire spectrum
of scores in our database.
Finally, we compared our scoring results to those
obtained from two recently published studies based
on whole exome sequencing of ASD cohorts [11,
23]. We observed a moderate, but highly significant,
correlation (RPearson = 0.4; P = 6.6 × 10
−19) between
the TGS of the 461 genes in our study and their
corresponding posterior probabilities [23] (Fig. 4c).
Nevertheless, only 63 (13.7 %) of these genes had a
posterior probability of ≥0.8 that was suggested by
Iossifov et al. [23] as good candidate ASD genes
(Fig. 4a). Furthermore, of the 65 ASD risk genes re-
ported by Sanders et al. [11], 44 (67.7 %) were in-
cluded in our dataset (Fig. 4a). Here too, we
observed strong correlation between the TGS of
these genes and their reported ranking in that study
(Fig. 4d; RSpearman = −0.41; p= 4.9 × 10
−20).
Discussion
Given the accelerated pace of ASD candidate gene dis-
covery, it is critical that resources be available to the re-
search community that not only catalog the identified
variants in detail but also provide tools to evaluate the
potential risk conferred by each individual variant. In
this report, we describe a systematic variant scoring
strategy utilizing the autism gene database AutDB that
encompasses detailed annotation of both rare and com-
mon genetic variants associated with ASD for candidate
gene prioritization. The large set of variants analyzed
here was extracted from studies that varied in size—from
single case reports to analysis of large cohorts such as the
Simons Simplex Collection. Additionally, our dataset in-
cluded variants identified by a variety of methodologies
ranging from targeted sequencing to whole genome-based
screening. While a number of other recent analyses of
ASD genes have focused on rare damaging de novo muta-
tions in simplex ASD cases, our study design also allowed
the inclusion of inherited autosomal recessive variants and
variants observed in multiplex and multigenerational
families.
This scoring approach identified three ASD risk genes
(SHANK3, CHD8, and ADNP) that exhibited significantly
higher scores than all other genes. SHANK3 was first re-
ported as an ASD candidate gene based on identification
of heterozygous mutations in ASD probands from three
unrelated families [24]. Subsequently, additional variants
in SHANK3 have been identified by targeted sequencing
Fig. 3 Gene scores distribution. a A histogram of the natural
logarithm of the total gene score (LnTGS) of the 461 genes
associated with autism spectrum disorder in this study. Three genes
(ADNP, CHD8, and SHANK3) have distinctly larger scores than all
other genes in the dataset. b A scatterplot of the expected LnTGS
according to a linear regression model based on the number of
variants per gene vs. the observed LnTGS. 95 and 99 % confidence
intervals (CI) of the predicted scores are depicted in dotted and
dashed lines, respectively
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in multiple ASD cohorts [15, 25]. In contrast, the risk con-
ferred by functional variants in CHD8 and ADNP have
only recently been described by WES studies of large ASD
cohorts [9], followed by smaller studies focused exclusively
on the identification of variants within these two genes
[25, 26]. However, comparable WES studies of large ASD
cohorts have failed to identify a large number of functional
variants in SHANK3, due in part to the high GC content
of this gene, which complicates WES approaches. These
findings clearly indicate the importance of considering
genetic evidence from multiple sources and multiple ex-
perimental methodologies in accurately prioritizing ASD
candidate genes.
A comparison of the prioritized gene list generated by
our scoring model with three other recently published
ASD-related gene lists [11, 22, 23] demonstrated strong
agreement in all three instances, confirming the validity
of our approach. Differences in the ranking of autism
candidates between our approach and these previous
studies are largely due to our exclusive focus on the vari-
ant’s/gene’s role in autism, not other neurodevelopmen-
tal diseases. For example, in our approach, a candidate
gene’s score is entirely dependent on the attributes of
the ASD-specific genetic variants; we excluded variants
from scoring when associated with a neurodevelopmen-
tal disorder without an accompanying diagnosis of ASD.
By comparison, SFARI Gene Scoring takes into consider-
ation the broader involvement of an ASD gene in related
neurodevelopmental/neuropsychiatric disorders as well
as its biological role in relation to ASD. These differ-
ences in scoring approaches account at least in part for
the discrepancies in scores for genes such as RBFOX1
(Fig. 4b), a gene for which considerable functional evi-
dence exists including its role in regulating other ASD
genes [27, 28] and its involvement in ASD pathogenesis
as manifested by differential expression in postmortem
brain of ASD individuals [29]. As ASD itself is already a
heterogeneous diagnosis, we built our model specifically
on confirmed cases of ASD only so as to be as stringent
as possible to ensure our resultant prioritization scheme
is as specific to ASD as possible, as we believe this is
critical to the use of such lists both for basic science re-
searchers and especially clinicians.
An important aspect of our study is the inclusion of
common variations associated with ASD (Additional
file 4: Table S4). As previously indicated, MET had
the highest common variant score (CVS = 85) based
on replicated genetic association studies. Similarly, a
Fig. 4 A comparison to other ASD risk genes datasets. a Venn diagram of the 653 ASD risk genes included in AutDB, SFARI gene scoring module
[22], Iossifov et al. [23], and Sanders et al. [11]. b A distribution of TGS across the different categories of genes in the SFARI gene scoring
module (1 = “high confidence”; 2 = “strong candidate”; 3 = “suggestive evidence”; 4 = “minimal evidence”; 5 = “hypothesized”; 6 = “not supported”).
c A scatterplot comparing the TGS of the genes in AutDB to their corresponding posterior probabilities in Iossifov et al. [23]. Genes with posterior
probabilities ≥0.8 are highlighted in red. d A distribution of TGS across the different categories of genes reported in Table 4 of Sanders et al. [11].
Categories indicate the probability pf genes to be ASD risk genes (1 = FDR≤ 0.01; 2 = 0.01 < FDR ≤ 0.05; 3 = 0.05 < FDR ≤ 0.1; 4 = 0.1 < FDR
Larsen et al. Molecular Autism  (2016) 7:44 Page 6 of 8
higher evidence category was assigned to MET in the
expert-mediated scoring in SFARI Gene. Multiple
lines of research indicate an important functional role
for MET in ASD [30]. However, the role of common
variants with small effect size remains poorly under-
stood in ASD as compared to their role in other
neuropsychiatric disorders such as schizophrenia and
bipolar disorder. In these other disorders, a number
of common variants have reached genome-wide sig-
nificance across multiple studies; common variants in
ASD have by and large failed to show similar replica-
tion across independent cohorts [31, 32].
Of note is the concern that more commonly studied
genes will have more variants in the database simply by
virtue of having been assessed more often and therefore
will rank higher in any prioritization scheme. In fact, we
did find significant correlations between the total variant
scores and the number of publications from which vari-
ants for a gene were extracted. This represents some-
what of a “winner’s curse” phenomenon reflecting
heightened attention from the ASD research community
for select genes. Nevertheless, the number of reported
variants per gene (which partially reflects the scientific
interest in these genes) explained only ~50 % of the
variations in scores—highlighting the comprehensive
nature our scoring algorithm. As more unbiased
whole exome and whole genome sequencing studies
are undertaken and added to this database, this effect
should continue to diminish. Furthermore, ongoing
future development of our algorithm will attempt to
correct for such effects.
Conclusions
In conclusion, we describe the most comprehensive
database to date of both common and rare DNA variants
associated with ASD. Using our novel scoring and rank-
ing algorithm that considers both genetic and biologic
data, we systematically characterized all classes of vari-
ants implicated in ASD on one platform and provide a
summary score for each ASD-associated genes (Additional
file 4: Table S4), which for the first time allows for a fair
comparison of ASD-associated gene relevance irrespective
of the type, number, or quality of study in which the
underlying variant(s) were identified. In addition to
strong ASD genes such as CHD8, ADNP, and SCN2A
recurrently identified by WES, our prioritized gene
set includes SHANK3, MET, and CNTNAP2 sup-
ported by multiple lines of genetic evidence, however
missed by WES. This database and ranking system
represents an important step in moving from simply
cataloging ASD genes to using unbiased, data-driven
approaches to determine the relative strength of asso-
ciation with ASD of each gene. This resource, which
is free to access and will continually be updated, will
serve as an important tool to both basic scientists
and clinicians working with ASD patients.
Additional files
Additional file 1: Figure S1. Gene scoring process. (A) A flowchart
describing the curation of both rare and common variants that are used
in the overall scores of genes associated with autism spectrum disorder.
(B) A formula for gene score calculation based on rare variants. (C) A
formula for gene score calculation based on common variants. (TIF 1424 kb)
Additional file 2: Supplementary methods. (DOCX 12 kb)
Additional file 3: Tables S1–S3. Variant scoring criteria. Tables of
scoring criteria common to both rare and common variants (Additional
file 3: Table S1), scoring criteria specific for rare variants (Additional file 3:
Table S2), and scoring criteria specific for common variants (Additional
file 3: Table S3). (DOCX 19 kb)
Additional file 4: Table S4. Scores of ASD candidate genes using the
scoring algorithm. Total gene scores were determined from the total
score of all rare variants (RVS) and the total score of all common variants
(CVS) for a given candidate gene. The coding sequence length of a
candidate gene, the number of publications from which rare and common
variants were extracted (Pub_Rare and Pub_Common, respectively), and the
number of scored rare and common variants (Var_Rare and Var_Comm,
respectively) are included for each gene. (XLSX 33 kb)
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